Medtronic plc (MDT) recently announced positive results demonstrating the safety and efficacy of the Affera Mapping and Ablation System with the Sphere-9 Catheter. The SPHERE Per-AF study, an FDA Investigational Device Exemption (“IDE”) pivotal trial, compared Sphere-9 to the conventional Thermocool SmartTouch SF radiofrequency ablation catheter with the Carto 3 System.The late-breaking clinical data was presented at the Heart Rhythm Society 2024 Annual Meeting and simultaneously published in Nature Medicin ...

 Award recognizes the commitment of Medtronic to revolutionizing diabetes care DUBLIN, May 20, 2024  /PRNewswire/ -- Fast Company announced that the Medtronic MiniMed™ 780G automated insulin delivery system has been recognized in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards. Fast Company's annual World Changing Ideas list celebrates organizations that pursue innovation for good. This is the fourth consecutive year Medtronic has been recognized on the l ...

Wall Street analysts expect Medtronic (MDT) to post quarterly earnings of $1.45 per share in its upcoming report, which indicates a year-over-year decline of 7.6%. Revenues are expected to be $8.44 billion, down 1.3% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a c ...

Core Insights - The SPHERE Per-AF trial shows that the Affera™ Mapping and Ablation System with Sphere-9™ Catheter provides excellent safety and efficacy for treating persistent atrial fibrillation (AFib) [1][2][4] Group 1: Study Results - Sphere-9 Catheter achieved a freedom from AFib rate of 73.8%, compared to 65.8% in the control group [3] - The primary safety endpoint rate for Sphere-9 was 1.4%, significantly lower than the control arm's 1.0%, with no reported safety events such as pulmonary vein stenosis or cardiac tamponade [2][3] - More than 95% of Sphere-9 procedures utilized a single transeptal puncture, compared to 62% in the control group [2] Group 2: Efficiency and Quality of Life - Sphere-9 demonstrated superior efficiency in procedural characteristics, including skin-to-skin procedural time and energy application time [3] - Patients treated with Sphere-9 reported improvements in both mental and physical quality of life [3] Group 3: Technology and Market Potential - The Sphere-9 Catheter features an all-in-one design with dual energy capabilities, integrating pulsed field and radiofrequency ablation [5][6] - The company has filed for FDA approval for the Sphere-9 Catheter in the U.S., with the device already receiving CE Mark approval in March 2023 [6][4] Group 4: Industry Context - AFib affects over 60 million people globally and is often undertreated, with persistent AFib patients making up 30-50% of the population [7] - The results from the SPHERE Per-AF trial are expected to significantly impact the treatment workflow in the electrophysiology community [6]

Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart Rhythm DUBLIN and BOSTON, May 17, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that its investigational OmniaSecure™ defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivot ...

Medtronic (MDT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this medical device company have returned +8.2%, compared to the Zacks S&P 500 composite's +5% change. During this period, the Zacks Medical - Products industry, which Medtronic falls in, has gained 3.5%. The key question now is: What could be the stock's future direction?Although media repor ...

In the latest trading session, Medtronic (MDT) closed at $83.52, marking a +0.82% move from the previous day. This move outpaced the S&P 500's daily loss of 0.02%. Meanwhile, the Dow lost 0.21%, and the Nasdaq, a tech-heavy index, added 0.29%.Shares of the medical device company witnessed a gain of 3.38% over the previous month, beating the performance of the Medical sector with its gain of 1.65% and the S&P 500's gain of 1.29%.The upcoming earnings release of Medtronic will be of great interest to investor ...

Company hosting in-person R&D day event, focused on atrioventricular interval modulation ("AVIM") therapy, including the unmet need in hypertension, mechanism of action, clinical results and design of the BACKBEAT study in New York City on June 11, 2024 NEW HOPE, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today repor ...

Medtronic (MDT) is expected to release fourth-quarter fiscal 2024 results on May 23 before the opening bell.Let’s delve into the factors that might have influenced this medical device major’s results in this to-be-reported quarter. However, it’s worth taking a look at MDT’s previous-quarter performance first.Impressive Surprise HistoryThe company posted adjusted earnings per share (EPS) of $1.30 in the last reported quarter, which topped the Zacks Consensus Estimate by 3.17%. Medtronic beat earnings estimat ...

DUBLIN, May 9, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's fourth quarter and full fiscal year 2024, which ended on Frida ...